- Posted June 28, 2013
- Tweet This | Share on Facebook
Esperion Therapeutics shares jump in trading debut
NEW YORK (AP) -- Shares of Esperion Therapeutics Inc. jumped Wednesday in their first day of trading after the drug developer raised $70 million in an initial public offering.
In midday trading, the drug developer's shares rose $1.27, or 9 percent, to $15.27, after jumping as high as $17.40 earlier in the session. Earlier, Esperion sold 5 million shares for $14 each, resulting in $70 million in proceeds.
Esperion is developing a new kind of experimental drug that would lower LDL cholesterol, commonly known as "bad" cholesterol. Roger Newton, the company's founder, executive chairman and chief scientific officer, is a co-discoverer of the cholesterol drug Lipitor, the world's top-selling drug for more than a decade.
The shares are trading on the Nasdaq under the ticker symbol "ESPR." The company is based in Plymouth, Mich.
Published: Fri, Jun 28, 2013
headlines Oakland County
- Attorneys sharpen courtroom skills at inaugural program
- Michigan tax preparers indicted for conspiring to defraud the United States and preparing false tax returns
- Woman pleads no contest on multiple cases, including embezzlement of $90K from her father
- As the country turns 250, retired judges hit the road to defend judicial independence
- Private mobile home water services provider, president sentenced for falsifying water safety, discharge tests
headlines National
- ABA connects death row inmate to pro bono attorneys who help free him
- ACLU and BigLaw firm use ‘Orange is the New Black’ in hashtag effort to promote NY jail reform
- 2 judges suspended in separate cases after being indicted on criminal charges
- Convicted ex-judge gets $5K fine but no prison time in immigration case
- Ohio governor signs bill prohibiting foreign litigation funding
- Many small firms collect payments faster than BigLaw counterparts, new data shows
